Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00328705 · ClinicalTrials.gov registry record · NA

D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management

A NA study of Heart Diseases, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

Completed
Registry status
NA
Development phase
65
Enrollment target
5
Study locations

NCT00328705 is a NA study of Heart Diseases that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 65 participants, below the 5,531-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00328705, a NA study of Heart Diseases, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.

COMPLETED
Registry status
NA
Development phase
65 participants
Enrollment target
5
Study locations

Study Summary

This is an acute, prospective, multi-center, non-randomized, investigational device exemption (IDE) clinical study.

Conditions Studied

Interventions

  • DEVICE Implantable Cardioverter Defibrillator

Study Locations (5)

Minnesota

  • - Coon Rapids
  • - Rochester
  • - Saint Paul

Florida

  • - Tampa

North Carolina

  • - Charlotte

Trial Details

FieldValue
Enrollment Target 65 participants
Start Date 2006-05
Est. Completion 2007-01
Phase NA

What the Registry Record Tells You About NCT00328705

The ClinicalTrials.gov registry entry for NCT00328705 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,531-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Diseases appearing as the primary indexed condition, and to 1 intervention - of which Implantable Cardioverter Defibrillator is the first listed.

NCT00328705 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT00328705 about?

NCT00328705 is a clinical study titled "D2-EPG Study: Evaluation of New Sensing Circuitry and Capture Management". This is an acute, prospective, multi-center, non-randomized, investigational device exemption (IDE) clinical study.

What is the current status of trial NCT00328705?

This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2006-05. Estimated completion is 2007-01.

What conditions does trial NCT00328705 study?

This clinical trial studies the following conditions: Heart Diseases.

What interventions are being tested in trial NCT00328705?

The interventions under investigation include: Implantable Cardioverter Defibrillator (DEVICE).

Who is sponsoring clinical trial NCT00328705?

This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00328705 being conducted?

This trial has 5 study locations across Florida, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.